JP2002502379A5 - - Google Patents

Download PDF

Info

Publication number
JP2002502379A5
JP2002502379A5 JP1998550755A JP55075598A JP2002502379A5 JP 2002502379 A5 JP2002502379 A5 JP 2002502379A5 JP 1998550755 A JP1998550755 A JP 1998550755A JP 55075598 A JP55075598 A JP 55075598A JP 2002502379 A5 JP2002502379 A5 JP 2002502379A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP1998550755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002502379A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/010807 external-priority patent/WO1998052937A2/en
Publication of JP2002502379A publication Critical patent/JP2002502379A/ja
Publication of JP2002502379A5 publication Critical patent/JP2002502379A5/ja
Abandoned legal-status Critical Current

Links

JP55075598A 1997-05-22 1998-05-22 ｐ３８キナーゼインヒビターとしての３（５）−ヘテロアリール置換ピラゾール Abandoned JP2002502379A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4753597P 1997-05-22 1997-05-22
US60/047,535 1997-05-22
PCT/US1998/010807 WO1998052937A2 (en) 1997-05-22 1998-05-22 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase

Publications (2)

Publication Number Publication Date
JP2002502379A JP2002502379A (ja) 2002-01-22
JP2002502379A5 true JP2002502379A5 (https=) 2005-11-24

Family

ID=21949533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP55075598A Abandoned JP2002502379A (ja) 1997-05-22 1998-05-22 ｐ３８キナーゼインヒビターとしての３（５）−ヘテロアリール置換ピラゾール

Country Status (14)

Country Link
US (1) US5932576A (https=)
EP (1) EP0983260A2 (https=)
JP (1) JP2002502379A (https=)
KR (1) KR20010012808A (https=)
CN (1) CN1264376A (https=)
AR (1) AR037061A1 (https=)
AU (1) AU755498B2 (https=)
BR (1) BR9809451A (https=)
CA (1) CA2288741A1 (https=)
IL (1) IL132736A0 (https=)
NO (1) NO995635D0 (https=)
PL (1) PL336990A1 (https=)
RU (1) RU2249591C2 (https=)
WO (1) WO1998052937A2 (https=)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US6087496A (en) 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
CA2294057A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
MXPA00006233A (es) * 1997-12-22 2002-09-18 Bayer Ag Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas.
MY132496A (en) * 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US7605149B1 (en) 1998-07-13 2009-10-20 University Of South Florida Modulation of the phospholipase A2 pathway as a therapeutic
CA2346665A1 (en) 1998-10-07 2000-04-13 Smithkline Beecham Corporation Novel treatment for stroke management
WO2000025791A1 (en) 1998-11-04 2000-05-11 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
WO2000035911A1 (en) 1998-12-16 2000-06-22 Aventis Pharma Limited Heteroaryl-cyclic acetals
AU765492B2 (en) * 1998-12-25 2003-09-18 Teikoku Hormone Mfg. Co., Ltd. Aminopyrazole derivatives
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2000281588A (ja) * 1999-03-30 2000-10-10 Sankyo Co Ltd ガンの予防又は治療薬及びそのスクリーニング方法
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1233951B1 (en) 1999-11-23 2005-06-01 SmithKline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
ATE305787T1 (de) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
HUP0202332A2 (en) 2000-02-05 2002-10-28 Vertex Pharma Pyrazole compositions useful as inhibitors of erk
WO2001056557A2 (en) * 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of erk
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
JP2004521915A (ja) * 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ過剰発現に対するピラゾール誘導体
MXPA03009378A (es) 2001-04-13 2004-01-29 Vertex Pharma Inhibidores de cinasas c-jun n-terminales (jnk) y otras proteinas cinasas.
US7074801B1 (en) 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
ATE491701T1 (de) * 2001-08-03 2011-01-15 Vertex Pharma Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
US20040248950A1 (en) * 2001-08-24 2004-12-09 Natsuki Ishizuka Apo ai expression accelerating agent
KR100697482B1 (ko) 2001-09-25 2007-03-20 파마시아 코포레이션 치환된 피라졸의 제조 방법
US7057049B2 (en) 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
WO2003037362A2 (en) 2001-10-29 2003-05-08 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
EP1456180B1 (en) 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
EP2258687B1 (en) 2002-02-12 2012-12-26 Glaxosmithkline LLC Nicotinamide derivates useful as P38 inhibitors
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
US20050124620A1 (en) * 2002-04-09 2005-06-09 Martyn Frederickson Pharmaceutical compounds
KR101025675B1 (ko) 2002-04-23 2011-03-30 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 피롤로-트리아진 아닐린 화합물
JP2005529919A (ja) * 2002-05-10 2005-10-06 スミスクライン ビーチャム コーポレーション 治療用化合物
DE60310730T2 (de) 2002-07-09 2007-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
PL379544A1 (pl) * 2002-09-09 2006-10-02 Amgen Inc. 1,4,5-podstawione pochodne 1,2-dihydro-pirazol-3-onu i 3-alkoksy 1H-pirazolu jako środki obniżające poziom TNF-alfa oraz interleukin do leczenia stanów zapalnych
CA2497971A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors
MXPA05002332A (es) 2002-09-18 2005-06-08 Pfizer Prod Inc Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
HRP20050247A2 (en) 2002-09-18 2005-10-31 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
PL375973A1 (en) 2002-09-18 2005-12-12 Pfizer Products Inc. Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors
JP4547271B2 (ja) 2002-09-18 2010-09-22 ファイザー・プロダクツ・インク トランスフォーミング増殖因子（ｔｇｆ）阻害剤としての新規イミダゾール化合物
EP1553096B1 (en) * 2002-09-25 2012-10-31 Ube Industries, Ltd. Pyrazole compounds
KR20050096956A (ko) 2003-02-07 2005-10-06 다이이찌 세이야꾸 가부시기가이샤 피라졸 유도체
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
EP1606019A1 (en) * 2003-03-07 2005-12-21 The University Court of The University of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
EP1745791B1 (en) 2003-05-07 2013-06-26 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
US7652044B2 (en) * 2003-06-03 2010-01-26 Novartis A.G. P-38 inhibitors
KR101120857B1 (ko) 2003-06-26 2012-04-12 노파르티스 아게 5원의 헤테로사이클-기재 ｐ38 키나제 억제제
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
ATE482205T1 (de) 2003-07-25 2010-10-15 Novartis Ag P-38-kinasehemmer
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US7148348B2 (en) 2004-08-12 2006-12-12 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
PL1778686T3 (pl) 2004-08-12 2009-04-30 Pfizer Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
US20060235020A1 (en) * 2005-04-18 2006-10-19 Soojin Kim Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
US20060252807A1 (en) * 2005-04-22 2006-11-09 Kalypsys, Inc. Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
WO2007027878A2 (en) * 2005-08-31 2007-03-08 Emergent Product Development Gaithersburg Inc. 4-substituted 2-aryloxyphenol derivatives as antibacterial agents
WO2007049041A1 (en) * 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
BRPI0620415A2 (pt) * 2005-12-23 2011-11-08 Astrazeneca Ab composto e sais farmaceuticamente e farmacologicamente aceitáveis do mesmo, e enantiÈmeros do composto e sais do mesmo, composição farmaceutica, e, uso de um composto opcionalmente em combinação com um agonista do receptor de gabab, e, métodos para o tratamento de doença, de um distúrbio, e de sìndrome
CN101395158A (zh) * 2006-03-07 2009-03-25 百时美施贵宝公司 可作为激酶抑制剂的吡咯并三嗪苯胺前体药物化合物
JP2007205153A (ja) * 2006-08-07 2007-08-16 Seiki Hanbai Co Ltd 網戸用ネットの押さえ部材
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
JP2010508288A (ja) * 2006-10-27 2010-03-18 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なヘテロサイクリックアミド化合物
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
NZ578944A (en) * 2007-02-13 2011-03-31 Ab Science PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS SUCH AS 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide AS KINASE INHIBITORS
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
KR20210070407A (ko) 2007-08-29 2021-06-14 센주 세이야꾸 가부시키가이샤 각막 내피 세포 접착 촉진제
TW200948801A (en) * 2008-04-08 2009-12-01 Gruenenthal Gmbh Substituierte sulfonamid-derivate
JP2011525184A (ja) * 2008-06-20 2011-09-15 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なトリアゾロピリジン化合物
US8338604B2 (en) 2008-06-20 2012-12-25 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
JP2012506388A (ja) * 2008-10-23 2012-03-15 ロンザ リミテッド 置換されたピラゾールの合成方法
US20110082145A1 (en) * 2009-10-01 2011-04-07 Alcon Research, Ltd. Olopatadine compositions and uses thereof
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
AR079545A1 (es) 2009-12-21 2012-02-01 Bayer Cropscience Ag Tienilpiri(mi)dinilazol
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
WO2012031057A1 (en) 2010-09-01 2012-03-08 Bristol-Myers Squibb Company Bms- 582949 for the treatment of resistant rheumatic disease
WO2012175513A1 (en) 2011-06-20 2012-12-27 Bayer Intellectual Property Gmbh Thienylpyri(mi)dinylpyrazole
CN104039785A (zh) 2011-10-06 2014-09-10 拜耳知识产权有限责任公司 作为杀真菌剂的杂环基吡(嘧)啶基吡唑
RU2627272C2 (ru) 2011-10-06 2017-08-04 Байер Интеллектчуал Проперти Гмбх Гетероциклилпиридинилпиразолы
CN103360315B (zh) * 2013-07-22 2015-03-04 山东大学 一种芳杂氧乙酰肼类衍生物及其制备方法与应用
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2023164538A1 (en) * 2022-02-23 2023-08-31 Biohaven Therapeutics Ltd. Pyrazolyl compounds as kv7 channel activators

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1261124B (de) * 1961-09-22 1968-02-15 Hoechst Ag Verfahren zur Herstellung von Pyrazolen
GB1245283A (en) * 1968-10-04 1971-09-08 Labaz Pyrazole derivatives
US3984431A (en) * 1972-03-15 1976-10-05 Claude Gueremy Derivatives of pyrazole-5-acetic acid
FR2509729A1 (fr) * 1981-07-15 1983-01-21 Pharmindustrie Nouveau procede de preparation de derives du diphenyl-3,4 methyl-5 pyrazole
US5051518A (en) * 1987-05-29 1991-09-24 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
JP2753659B2 (ja) * 1990-09-03 1998-05-20 株式会社大塚製薬工場 ピラゾール誘導体
JPH04145081A (ja) * 1990-10-06 1992-05-19 Kumiai Chem Ind Co Ltd ピラゾールカルボン酸誘導体及び除草剤
AU1988692A (en) * 1991-04-24 1992-12-21 E.I. Du Pont De Nemours And Company Fungicidal pyrazoles, pyrazolines and tetrahydropyridazines
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
GB9204958D0 (en) * 1992-03-06 1992-04-22 Fujisawa Pharmaceutical Co Thiazole derivatives
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
DE4328228A1 (de) * 1993-08-23 1995-03-02 Basf Ag Verfahren zur Herstellung von Pyrazol und dessen Derivaten
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
JPH0899975A (ja) * 1994-08-05 1996-04-16 Nippon Bayeragrochem Kk ５員複素環置換テトラゾリノン誘導体および除草剤
JP3734180B2 (ja) * 1994-12-28 2006-01-11 エーザイ株式会社 新規ピラゾール誘導体
JPH11508267A (ja) * 1995-06-26 1999-07-21 藤沢薬品工業株式会社 ピラゾール化合物および医薬組成物
GB2361824B (en) * 2000-04-27 2004-05-26 Roke Manor Research Improvements in or relating to electronic timing systems

Similar Documents

Publication Publication Date Title
JP2000509912A5 (https=)
JP2000509637A5 (https=)
JP2000507042A5 (https=)
JP2000509635A5 (https=)
JP2000509942A5 (https=)
JP2000510751A5 (https=)
JP2002502379A5 (https=)
JP2000509587A5 (https=)
JP2000507369A5 (https=)
JP2000507433A5 (https=)
JP2000508866A5 (https=)
JP2000510793A5 (https=)
JP2000508022A5 (https=)
JP2000508841A5 (https=)
JP2000508680A5 (https=)
JP2000509804A5 (https=)
JP2000509853A5 (https=)
JP2000509755A5 (https=)
JP2000510247A5 (https=)
JP2000510969A5 (https=)
JP2000508102A5 (https=)
JP2000508836A5 (https=)
JP2000509520A5 (https=)
JP2000509818A5 (https=)
JP2000507434A5 (https=)